This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Pacific Biosciences For Now
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
Why Is Pacific Biosciences (PACB) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 11.11% and 10.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
46 and You: Genetic Testing = Giant Growth Market
by Kevin Cook
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
Pacific Biosciences (PACB) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall
by Zacks Equity Research
Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.
Will Pacific Biosciences of California (PACB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences (PACB) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -61.54% and -7.37%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LMNX or PACB: Which is a Better MedTech Investment Pick?
by Zacks Equity Research
Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.
Here's Why You Should Hold Pacific Biosciences (PACB) Now
by Zacks Equity Research
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Pacific Biosciences (PACB) Up 73.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
Pacific Biosciences Offers Insights on Aedes aegypti Genome
by Zacks Equity Research
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
by Zacks Equity Research
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -18.75% and -17.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences Introduces Enhancements to Sequel System
by Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
by Zacks Equity Research
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.